Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8382719rdf:typepubmed:Citationlld:pubmed
pubmed-article:8382719lifeskim:mentionsumls-concept:C0019682lld:lifeskim
pubmed-article:8382719lifeskim:mentionsumls-concept:C0019196lld:lifeskim
pubmed-article:8382719lifeskim:mentionsumls-concept:C0392353lld:lifeskim
pubmed-article:8382719lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:8382719lifeskim:mentionsumls-concept:C1549458lld:lifeskim
pubmed-article:8382719lifeskim:mentionsumls-concept:C0201773lld:lifeskim
pubmed-article:8382719pubmed:issue3lld:pubmed
pubmed-article:8382719pubmed:dateCreated1993-3-30lld:pubmed
pubmed-article:8382719pubmed:abstractTextThe prevalence of hepatitis A, B, C, and D viruses was studied in 467 military personnel with human immunodeficiency virus type 1 (HIV-1) infection. Antibody to hepatitis C virus (anti-HCV) by first-generation ELISA was found in 136 (29%). Of sera repeatedly reactive for anti-HCV by first-generation ELISA, two-antigen recombinant immunoblot assay (RIBA) was positive in 41 (32%) and four-antigen RIBA was positive in 55 (41%). Four-antigen RIBA was positive in 33 (30%) of the 109 with an OD on ELISA of < or = 2.0 compared with 22 (81%) of the 27 with an OD > 2.0 (P < .001). Anti-HCV detected by four-antigen RIBA was associated with increasing age, black or Hispanic race, and antibody to hepatitis B core antigen. When patients with hepatitis B surface antigen were excluded, elevated alanine aminotransferase was found in 5 (8%) of 63 with a negative RIBA and 13 (28%) of 47 with a positive RIBA (P = .006). While RIBA was negative in more than half of those with anti-HCV by ELISA, 55 (12%) of these HIV-1 infected personnel had anti-HCV detected by RIBA, which was associated with a strong reaction by ELISA, elevated liver enzymes, coinfection with hepatitis B, minority race, and older age.lld:pubmed
pubmed-article:8382719pubmed:languageenglld:pubmed
pubmed-article:8382719pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8382719pubmed:citationSubsetAIMlld:pubmed
pubmed-article:8382719pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8382719pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8382719pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8382719pubmed:statusMEDLINElld:pubmed
pubmed-article:8382719pubmed:monthMarlld:pubmed
pubmed-article:8382719pubmed:issn0022-1899lld:pubmed
pubmed-article:8382719pubmed:authorpubmed-author:WagnerKKlld:pubmed
pubmed-article:8382719pubmed:authorpubmed-author:SmithEElld:pubmed
pubmed-article:8382719pubmed:authorpubmed-author:PerineP LPLlld:pubmed
pubmed-article:8382719pubmed:authorpubmed-author:SjogrenM HMHlld:pubmed
pubmed-article:8382719pubmed:authorpubmed-author:MaloneJ LJLlld:pubmed
pubmed-article:8382719pubmed:authorpubmed-author:DASK MKMlld:pubmed
pubmed-article:8382719pubmed:authorpubmed-author:MacArthyPPlld:pubmed
pubmed-article:8382719pubmed:authorpubmed-author:BryanJ PJPlld:pubmed
pubmed-article:8382719pubmed:authorpubmed-author:SheffieldJJlld:pubmed
pubmed-article:8382719pubmed:issnTypePrintlld:pubmed
pubmed-article:8382719pubmed:volume167lld:pubmed
pubmed-article:8382719pubmed:ownerNLMlld:pubmed
pubmed-article:8382719pubmed:authorsCompleteYlld:pubmed
pubmed-article:8382719pubmed:pagination715-9lld:pubmed
pubmed-article:8382719pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:meshHeadingpubmed-meshheading:8382719-...lld:pubmed
pubmed-article:8382719pubmed:year1993lld:pubmed
pubmed-article:8382719pubmed:articleTitleRecombinant immunoblot assays for hepatitis C in human immunodeficiency virus type 1-infected US Navy personnel.lld:pubmed
pubmed-article:8382719pubmed:affiliationDept. of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4799.lld:pubmed
pubmed-article:8382719pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8382719pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed